VisionPoint Advisory Group’s Amneal Pharmaceuticals AMRX Stock Holding History

VisionPoint Advisory Group’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$217K	Buy	+10,751	New	+$194K	0.03%	428

Other funds holding AMRX

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

Stonebridge Financial Group (Pennsylvania) Wormleysburg, Pennsylvania $1.36B AUM 14.31% 1-Year Est. Return

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return

Bank of New Hampshire Laconia, New Hampshire $463M AUM 23.57% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

VisionPoint Advisory Group's AMRX Position: Q3 2026 in Review

VisionPoint Advisory Group opened a new position in Amneal Pharmaceuticals (AMRX) in Q3 2026: 10,751 shares worth $217K. The stake represents 0.03% of the portfolio and ranks #428 among its holdings.

14 funds tracked by Wall St. Rank hold AMRX as of Q3 2026.

VisionPoint Advisory Group held 10,751 shares of Amneal Pharmaceuticals worth $217K as of Q3 2026.
Amneal Pharmaceuticals was a new VisionPoint Advisory Group position in Q3 2026.
Amneal Pharmaceuticals made up 0.03% of VisionPoint Advisory Group's portfolio in Q3 2026, its #428 holding.
14 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2026.

Based on VisionPoint Advisory Group's 13F filing for Q3 2026, filed 9 Oct 2026.